Patents by Inventor Maxwell Stock
Maxwell Stock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240060093Abstract: Systems and methods for producing methanol are provided. A reformer feed gas including methane and carbon dioxide is provided to a methane reformer, which produces a synthesis gas. The synthesis gas includes a first portion of hydrogen, a second portion of carbon monoxide, and a third portion of carbon dioxide. The methane is present in the reformer feed gas in an amount of between 20 volume percent (vol %) and 90 vol % and the carbon dioxide is present in the reformer feed gas in an amount of between 10 vol % and 80 vol %. The synthesis gas is subjected to a methanol synthesis reactor. The methanol synthesis reactor is utilized to produce a methanol product and a purge gas stream from the synthesis gas.Type: ApplicationFiled: August 16, 2023Publication date: February 22, 2024Inventors: Mario E. De La Ossa, JR., Roberto Francisco Iannone, Steven Andrew Leppard, Ralph Maxwell Stock, Charles James Thompson
-
Patent number: 10912812Abstract: Method of preparing a botanical extract that includes contacting a raw botanical with a solvent having a dielectric constant ranging from about 2.3 to about 25 and allowing the mixture to reside for a sufficient time to obtain a crude extract; filtering out remaining raw botanical and evaporating the solvent from the crude extract under reduced pressure to obtain a dried crude extract; washing the dried crude extract with a polar solvent having a dielectric constant of no less than 30, heating the resulting mixture, and allowing to cool to ambient; collecting a filtrate from the above cooled mixture; washing the collected filtrate with a non-polar solvent having a dielectric constant of no more than 2.0; and filtering and drying the mixture to obtain the botanical extract.Type: GrantFiled: July 17, 2019Date of Patent: February 9, 2021Assignee: Signum Biosciences, Inc.Inventors: Kristen Huber, Michael Voronkov, Jose Fernandez, Karl Rouzard, Eduardo Perez, Maxwell Stock, Jeffry Stock
-
Patent number: 10583119Abstract: The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.Type: GrantFiled: November 8, 2016Date of Patent: March 10, 2020Assignee: Signum Biosciences, Inc.Inventors: Scott Vafai, Michael Voronkov, Maxwell Stock, Jeffry B. Stock, Seung-Yub Lee, Zhu Li, Haoming Gu
-
Publication number: 20190336561Abstract: Compositions containing natural and botanical extracts for use in inhibiting one, two, or three of (a)-(c): (a) demethylation of PP2A by PME-1 methylesterase; (b) formation of free radicals and reactive oxygen species; and/or (c) inflammation. These compositions include an extract of one or more botanicals selected from the group consisting of: juniper berry fruit, schisandra fruit, strawberry fruit, avocado seeds, black raspberry seeds, blueberry seeds, celery seeds, cranberry seeds, fennel seeds, grape seeds, guarana seeds, red raspberry seeds, maca root, goldenseal root, turmeric root, magnolia bark, pygeum bark, red raspberry leaf, almond, cocoa powder, Echinacea angustifolia, prickly pear cactus and walnut.Type: ApplicationFiled: July 17, 2019Publication date: November 7, 2019Applicant: Signum Biosciences, Inc.Inventors: Kristen Huber, Michael Voronkov, Jose Fernandez, Karl Rouzard, Eduardo Perez, Maxwell Stock, Jeffry Stock
-
Patent number: 10314802Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.Type: GrantFiled: August 1, 2017Date of Patent: June 11, 2019Assignee: Signum Biosciences, Inc.Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
-
Patent number: 10314817Abstract: EHT extract including a mixture of late eluting tryptamides and early eluting tryptamides in a weight ratio of at least about 7:1 late eluting tryptamides:early eluting tryptamides, wherein the EHT extract includes at least 30% eicosanoyl-5-hydroxytryptamide, based on the total weight of the tryptamides in the EHT extract.Type: GrantFiled: October 15, 2015Date of Patent: June 11, 2019Assignee: Signum Biosciences, Inc.Inventors: Jeffry Stock, Maxwell Stock, Michael Voronkov, Jose Fernandez, Kristen Huber
-
Patent number: 10117904Abstract: Disclosed herein are methods of inactivating and/or decolonizing bacteria on a surface. The present invention also discloses methods for treatment of epithelial conditions caused or aggravated by bacteria, such as acne vulgaris, in a subject in need thereof. The present invention additionally discloses inventive compounds and compositions that exhibit anti-bacterial and/or anti-inflammatory effects.Type: GrantFiled: July 27, 2016Date of Patent: November 6, 2018Assignee: Signum Biosciences, Inc.Inventors: Jeffry B. Stock, Maxwell Stock
-
Publication number: 20170368011Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.Type: ApplicationFiled: August 1, 2017Publication date: December 28, 2017Applicant: SIGNUM BIOSCIENCES, INC.Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
-
Publication number: 20170266161Abstract: The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.Type: ApplicationFiled: November 8, 2016Publication date: September 21, 2017Applicant: Signum Biosciences, Inc.Inventors: SCOTT VAFAI, Michael Voronkov, Maxwell Stock, Jeffry B. Stock, Seung-Yub Lee, Zhu Li, Haoming Gu
-
Patent number: 9744147Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.Type: GrantFiled: May 10, 2016Date of Patent: August 29, 2017Assignee: Signum Biosciences, Inc.Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
-
Publication number: 20170231955Abstract: EHT extract including a mixture of late eluting tryptamides and early eluting tryptamides in a weight ratio of at least about 7:1 late eluting tryptamides:early eluting tryptamides, wherein the EHT extract includes at least 30% eicosanoyl-5-hydroxytryptamide, based on the total weight of the tryptamides in the EHT extract.Type: ApplicationFiled: October 15, 2015Publication date: August 17, 2017Inventors: Jeffry STOCK, Maxwell STOCK, Michael VORONKOV, Jose FERNANDEZ, Kristen HUBER
-
Publication number: 20170224757Abstract: Compositions containing natural and botanical extracts for use in inhibiting one, two, or three of (a)-(c): (a) demethylation of PP2A by PME-1 methylesterase; (b) formation of free radicals and reactive oxygen species; and/or (c) inflammation. These compositions include an extract of one or more botanicals selected from the group consisting of: juniper berry fruit, schisandra fruit, strawberry fruit, avocado seeds, black raspberry seeds, blueberry seeds, celery seeds, cranberry seeds, fennel seeds, grape seeds, guarana seeds, red raspberry seeds, maca root, goldenseal root, turmeric root, magnolia bark, pygeum bark, red raspberry leaf, almond, cocoa powder, Echinacea angustifolia, prickly pear cactus and walnut.Type: ApplicationFiled: July 22, 2015Publication date: August 10, 2017Inventors: Kristen Huber, Michael Voronkov, Jose Fernandez, Karl Rouzard, Eduardo Perez, Maxwell Stock, Jeffry Stock
-
Publication number: 20170049841Abstract: Disclosed herein are methods of inactivating and/or decolonizing bacteria on a surface. The present invention also discloses methods for treatment of epithelial conditions caused or aggravated by bacteria, such as acne vulgaris, in a subject in need thereof. The present invention additionally discloses inventive compounds and compositions that exhibit anti-bacterial and/or anti-inflammatory effects.Type: ApplicationFiled: July 27, 2016Publication date: February 23, 2017Inventors: Jeffry B. Stock, Maxwell Stock
-
Publication number: 20160361283Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.Type: ApplicationFiled: May 10, 2016Publication date: December 15, 2016Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
-
Patent number: 9486441Abstract: The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.Type: GrantFiled: April 21, 2009Date of Patent: November 8, 2016Assignee: SIGNUM BIOSCIENCES, INC.Inventors: Scott Vafai, Michael Voronkov, Maxwell Stock, Jeffry B. Stock, Seung-Yub Lee, Zhu Li, Haoming Gu
-
Formulations Comprising Idebenone, N-Acetyl-S-Farnesyl-L-Cysteine and Ergothioneine and Uses Thereof
Publication number: 20160243011Abstract: Compositions that mitigate damage caused by environmental stressors are provided. The stressors include, but are not limited to, damage caused by ultra-violet radiation. The compositions comprise an effective amount of idebenone or a derivative thereof, N-acetyl-S-farnesyl-L-cysteine or a pharmaceutically acceptable salt or ester thereof and ergothioneine or a pharmaceutically acceptable salt or ester thereof. In some embodiments these compositions are applied topically to a person's skin.Type: ApplicationFiled: September 11, 2013Publication date: August 25, 2016Inventors: Jose Fernandez, Eduardo Perez, Maxwell Stock, Lavinia Codruta Popescu, Aurelie Nathalie Felix-Gonnot, Arthur Joseph Pellegrino -
Patent number: 9415026Abstract: Disclosed herein are methods of inactivating and/or decolonizing bacteria on a surface. The present invention also discloses methods for treatment of epithelial conditions caused or aggravated by bacteria, such as acne vulgaris, in a subject in need thereof. The present invention additionally discloses inventive compounds and compositions that exhibit anti-bacterial and/or anti-inflammatory effects.Type: GrantFiled: November 12, 2010Date of Patent: August 16, 2016Assignee: SIGNUM BIOSCIENCES, INC.Inventors: Jeffry B. Stock, Maxwell Stock
-
Patent number: 9376383Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.Type: GrantFiled: February 6, 2013Date of Patent: June 28, 2016Assignee: SIGNUM BIOSCIENCES, INC.Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen
-
Publication number: 20130310559Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.Type: ApplicationFiled: February 6, 2013Publication date: November 21, 2013Applicant: SIGNUM BIOSCIENCES, INC.Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
-
Patent number: 8461204Abstract: Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, the compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g.Type: GrantFiled: August 3, 2012Date of Patent: June 11, 2013Assignee: Signum Biosciences, Inc.Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen